Upexi (Nasdaq:UPXI) - Stock Price, News & Analysis

UPXI Stock Overview

Manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets.

UPXI fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Trading at good value compared to peers and industry

Risk Analysis

Has less than 1 year of cash runway

Does not have a meaningful market cap ($4M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

+ 1 more risk

Upexi, Inc. Competitors

Shineco

NasdaqCM:SISI

US$8.4m

Cordyceps Sunshine Biotech Holdings

OTCPK:RAJA.F

US$4.4m

NuVibe

OTCPK:KGKG

US$1.7m

LFTD Partners

OTCPK:LIFD

US$9.6m

Price History & Performance

Summary of all time highs, changes and price drops for Upexi
Historical stock prices
Current Share Price	US$0.20
52 Week High	US$1.99
52 Week Low	US$0.18
Beta	0.45
11 Month Change	3.86%
3 Month Change	-55.28%
1 Year Change	-88.59%
33 Year Change	-96.04%
5 Year Change	n/a
Change since IPO	-96.39%

Recent updates

Shareholder Returns

	UPXI	US Personal Products	US Market
7D	3.8%	-0.9%	1.6%
1Y	-88.6%	-16.0%	30.5%

Return vs Industry: UPXI underperformed the US Personal Products industry which returned -15% over the past year.

Return vs Market: UPXI underperformed the US Market which returned 30.5% over the past year.

Price Volatility

Is UPXI's price volatile compared to industry and market?
UPXI volatility
UPXI Average Weekly Movement	13.5%
Personal Products Industry Average Movement	8.3%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

Stable Share Price: UPXI's share price has been volatile over the past 3 months.

Volatility Over Time: UPXI's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2018	95	Allan Marshall	www.upexi.com

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

Upexi, Inc. Fundamentals Summary

How do Upexi's earnings and revenue compare to its market cap?
UPXI fundamental statistics
Market cap	US$4.41m
Earnings (TTM)	-US$22.92m
Revenue (TTM)	US$83.98m

0.1x

P/S Ratio

-0.2x

P/E Ratio

Is UPXI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
UPXI income statement (TTM)
Revenue	US$83.98m
Cost of Revenue	US$54.43m
Gross Profit	US$29.55m
Other Expenses	US$52.47m
Earnings	-US$22.92m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.10
Gross Margin	35.19%
Net Profit Margin	-27.29%
Debt/Equity Ratio	120.9%

How did UPXI perform over the long term?

See historical performance and comparison

UPXI Stock Overview

Rewards

Risk Analysis

Upexi, Inc. Competitors

NasdaqCM:SISI

US$8.4m

OTCPK:RAJA.F

US$4.4m

OTCPK:KGKG

US$1.7m

OTCPK:LIFD

US$9.6m

Price History & Performance

Recent News & Updates

Insufficient new directors

David Romano, Nick Romano and Eric Limont acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million.

E-Core Holdings, LLC acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million.

Upexi Provides Update on Filing Form 10Q for March 31, 2024

Upexi, Inc. to Report Q3, 2024 Results on Jun 24, 2024

MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC acquired VitaMedica Corporation from Upexi, Inc. (NasdaqCM:UPXI) for $6 million.

Recent updates

Insufficient new directors

David Romano, Nick Romano and Eric Limont acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million.

E-Core Holdings, LLC acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million.

Upexi Provides Update on Filing Form 10Q for March 31, 2024

Upexi, Inc. to Report Q3, 2024 Results on Jun 24, 2024

MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC acquired VitaMedica Corporation from Upexi, Inc. (NasdaqCM:UPXI) for $6 million.

Upexi, Inc. announced delayed 10-Q filing

Upexi, Inc., Annual General Meeting, Jun 10, 2024

New major risk - Market cap size

Upexi Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Consensus revenue estimates fall by 17%

Consensus revenue estimates fall by 17%

This Analyst Just Downgraded Their Upexi, Inc. (NASDAQ:UPXI) EPS Forecasts

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Upexi, Inc. Revises Preliminary and Unaudited Financial Guidance for the First Quarter Ended September 30, 2023

Upexi, Inc. announced delayed 10-Q filing

Upexi, Inc. Pet Care Brand, Luckytail, Announces Expansion of Product Line to Include All-Natural Dog Supplements

Amplifyir Inc. acquired 100% stake in Interactive Offers LLC from Upexi, Inc. (NasdaqCM:UPXI) for $1.25 million.

Upexi, Inc. (NASDAQ:UPXI) Doing What It Can To Lift Shares

Upexi, Inc., Annual General Meeting, Jun 26, 2023

Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.003 loss in 3Q 2022)

Investor sentiment deteriorates as stock falls 16%

Upexi, Inc. announced delayed 10-Q filing

Second quarter 2023 earnings released: EPS: US$0.17 (vs US$0.004 in 2Q 2022)

CEO, President & Chairman of the Board recently bought US$73k worth of stock

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.033 profit in 1Q 2022)

High number of new and inexperienced directors

Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of E-Core, Inc.

Bloomios, Inc. (OTCPK:BLMS) acquired Infusionz, LLC from Upexi, Inc. (NasdaqCM:UPXI) for $23.5 million.

Upexi, Inc. Files Patent for its Single Click-to-optin Technology

Upexi, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Full year 2022 earnings released: US$0.13 loss per share (vs US$0.25 profit in FY 2021)

Upexi, Inc. Appoints Anthony Bazan as Chief Operating Officer

Investor sentiment deteriorated over the past week

Grove, Inc. (NasdaqCM:GRVI) signed a non-binding LOI to acquire E-Core, Inc.

Investor sentiment improved over the past week

Grove CEO provides company update on sales and beyond

Investor sentiment improved over the past week

Grove, Inc.(NasdaqCM:GRVI) dropped from Russell Microcap Value Index

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Grove, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.071 profit in 3Q 2021)

High number of new and inexperienced directors

Grove, Inc. (NasdaqCM:GRVI) acquired Cygnet Online LLC.

Grove, Inc., Annual General Meeting, May 24, 2022

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

High number of new and inexperienced directors

First quarter 2022 earnings released: EPS US$0.033 (vs US$0.078 loss in 1Q 2021)

Investor sentiment improved over the past week

Why Grove's (NASDAQ:GRVI) Earnings Are Weaker Than They Seem

Full year 2021 earnings released: EPS US$0.25 (vs US$0.53 loss in FY 2020)

Grove, Inc. (NasdaqCM:GRVI) signed a letter of intent to acquire Interactive Offers LLC.

Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of VitaMedica Corporation.

Grove: An Underrated CBD Player

Grove, Inc. (NasdaqCM:GRVI) entered into a non binding letter of intent to acquire VitaMedica Corporation.

Grove, Inc. has completed an IPO in the amount of $11 million.